Fundraising Fox
Ligand
NASDAQ: LGNDalso invests · investor profileLa Jolla, US · 3 known investors
Find your way into Ligand
Sign up to see every warm intro you have to Ligand
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ligand team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ligand is a royalty aggregator that finances late-stage clinical development and commercialization programs for biopharmaceutical companies. The company maintains a diversified portfolio of royalty assets across oncology, rare diseases, and other therapeutic areas, and licenses proprietary technology platforms to pharmaceutical manufacturers.
Founders & leadership
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$85.4M disclosed across 1 round · 2016
▶$85.4MraisedJan 2016 · 22 investors · PharmaceuticalsRule 506(c)
- MATTHEW W. FOEHRDirector
- JOHN L. HIGGINSExecutive Officer, Director
- JOHN LAMATTINADirector
- TODD DAVISDirector
- SUNIL PATELDirector
- JOHN KOZARICHDirector
- MATTHEW KORENBERGDirector
- DAVID M. KNOTTDirector
- JASON ARYEHDirector
- CHARLES S. BERKMANDirector
- STEPHEN SABBADirector
- MELANIE HERMANDirector
- Offering amount
- $85.4M
- Amount sold
- $85.4M
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Ligand went on to found or lead other companies.
Acquisitions · 1
Early investors' stakes continue via these dealsXOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding. It serves biotech companies seeking capital to advance their internal drug candidates, holding a portfolio of 120+ assets.
In the news
Frequently asked questions
- What does Ligand do?
- Ligand is a royalty aggregator that finances late-stage clinical development and commercialization programs for biopharmaceutical companies. The company maintains a diversified portfolio of royalty assets across oncology, rare diseases, and other therapeutic areas, and licenses proprietary technology platforms to pharmaceutical manufacturers.
- Who founded Ligand?
- Ligand was founded by Brook Byers.
- Who are Ligand's investors?
- Ligand's investors include Signet Healthcare Partners, Sofinnova Ventures, Venrock.
- How much funding has Ligand raised?
- Ligand has disclosed $85.4M raised across 1 round.
- Where is Ligand headquartered?
- Ligand is headquartered in La Jolla, US.